Richard Taubert
Overview
Explore the profile of Richard Taubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taubert R, Kabbani M, Walter S, Goudeva L, Hartleben B, Stolzel U, et al.
Clin Res Hepatol Gastroenterol
. 2025 Mar;
49(4):102557.
PMID: 40023442
No abstract available.
2.
Snijders R, Janik M, Mund M, Uhlenbusch N, Raszeja-Wyszomirska J, Gerussi A, et al.
Hepatology
. 2025 Feb;
PMID: 39970194
Background: Impaired health-related quality of life (HRQoL) contributes to the overall disease burden in autoimmune hepatitis (AIH). This study aimed to evaluate HRQoL in people with AIH and to identify...
3.
Engel B, Assis D, Bhat M, Clusmann J, Drenth J, Gerussi A, et al.
JHEP Rep
. 2025 Feb;
7(2):101265.
PMID: 39897612
Autoimmune hepatitis (AIH) is a rare chronic liver disease with an increasing incidence in many countries. Chronic autoimmune responses against the liver can cause hepatic and extrahepatic symptoms, decreased quality...
4.
Campos-Murguia A, Hupa-Breier K, Hartleben B, Wedemeyer H, Taubert R, Engel B
Transplant Direct
. 2025 Jan;
10(3):e1592.
PMID: 39877649
Background: The noninvasive detection of subclinical graft injury including subclinical T cell-mediated rejection (subTCMR) is one of the unresolved challenges after liver transplantation. Recently, serum C-X-C motif chemokine ligand 8...
5.
Hupa-Breier K, Schenk H, Campos-Murguia A, Wellhoner F, Heidrich B, Dywicki J, et al.
Mol Metab
. 2025 Jan;
93:102104.
PMID: 39855563
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease, especially in patients with severe obesity. However, current mouse models for MASLD do not...
6.
Gerussi A, Saldanha O, Cazzaniga G, Verda D, Carrero Z, Engel B, et al.
JHEP Rep
. 2025 Jan;
7(2):101198.
PMID: 39829723
Background & Aims: Biliary abnormalities in autoimmune hepatitis (AIH) and interface hepatitis in primary biliary cholangitis (PBC) occur frequently, and misinterpretation may lead to therapeutic mistakes with a negative impact...
7.
Vionnet J, Torres-Yaguana J, Miquel R, Abraldes J, Wall J, Kodela E, et al.
Am J Transplant
. 2024 Dec;
PMID: 39706366
The maintenance of stable allograft status in the absence of immunosuppression (IS), known as operational tolerance, can be achieved in a small proportion of liver transplant recipients, but we lack...
8.
Campos-Murguia A, Guetzlaff L, Bosselmann E, Engel B, Hartleben B, Wedemeyer H, et al.
Clin Transplant
. 2024 Nov;
38(11):e70039.
PMID: 39575514
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading indication for liver transplantation (LT), but also occurs after LT. The prevalence of de novo MASLD (dnMASLD) after...
9.
Pape T, von Garrel T, Hunkemoller A, Nalbant B, Vondran F, Richter N, et al.
Abdom Radiol (NY)
. 2024 Nov;
PMID: 39500762
Purpose: Biliary strictures are among the most common complications following liver transplantation (LT). If endoscopic retrograde cholangiography fails, percutaneous transhepatic biliary drainage (PTBD) may serve as an alternative approach. Description...
10.
Markovic J, Li R, Khanal R, Peng Q, Mobus S, Yuan Q, et al.
J Hepatol
. 2024 Sep;
82(2):301-314.
PMID: 39218230
Background & Aims: Liver fibrosis and its end-stage form cirrhosis contribute to millions of deaths annually. The lack of robust antifibrotic molecules is in part attributed to the absence of...